Last reviewed · How we verify
Placebo equivalent
A placebo equivalent produces no pharmacological effect and serves as an inert control in clinical research and therapeutic contexts.
A placebo equivalent produces no pharmacological effect and serves as an inert control in clinical research and therapeutic contexts. Used for Clinical trial control comparator (non-therapeutic use).
At a glance
| Generic name | Placebo equivalent |
|---|---|
| Also known as | Placebo |
| Sponsor | Hospital Civil de Guadalajara |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos are inactive substances or procedures designed to mimic active treatments without containing any therapeutically active ingredients. They are used primarily in clinical trials to establish baseline efficacy through comparison with active drugs, and can produce measurable clinical benefits through psychobiological mechanisms including expectation and conditioning effects.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
- Placebo response (symptom improvement without active ingredient)
Key clinical trials
- A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis (PHASE2)
- The Impact of OliPhenolia® Supplementation on Exercise Induced Inflammation and Functional Movement in Humans. (NA)
- Multi-Center Study of Panosyl-Isomaltooligosaccharides Adjunctive to PPI Therapy to Treat GERD (PHASE2)
- Bleeding Reduction in Acute and Chronic Kidney Patients Having Surgery (BRACKETS) Pilot Trial (PHASE3)
- Wireless Nerve Stimulation Device To Enhance Recovery After Stroke (NA)
- A Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab as Adjunct Treatment in Prevention of Vaso-Occlusive Episodes (VOE) in Sickle Cell Disease (SCD) (PHASE2)
- Intravenous Lidocaine Infusion in Lumbar Fusion Surgery (NA)
- Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo equivalent CI brief — competitive landscape report
- Placebo equivalent updates RSS · CI watch RSS
- Hospital Civil de Guadalajara portfolio CI